AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11011807
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) tinzaparin, dosage regimen not specified
Trial: 9369265
Drug: SR 49059
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 49059 (300 mg)
Trial: 23092692
Drug: Multispecies combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies combination containing Lactobacillus rhamnosus GG
Trial: 26541658
Drug: Metronidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (500 mg q8 h orally for 7 days)
Trial: 21964491
Drug: G‐CSF (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (300 μg)
Trial: 21478189
Drug: Infliximab 6
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 6 mg/kg
Trial: 12010361
Drug: Lamivudine (3TC)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (3TC) treatment in the presence of M184V mutation
Trial: 24621971
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 3 g/day
Trial: 7027432
Drug: Aspirin 3
RxNorm normalized name: aspirin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 3 g
Trial: 28229278
Drug: Vitamin D3-fortified
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3-fortified doogh (FD; containing 170 mg calcium and 500 IU/250 mL)
Trial: 26004966
Drug: Prilocaine in
RxNorm normalized name: prilocaine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine in tumescent solution
Trial: 21641345
Drug: SLV320 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV320 1.25 mg
Trial: 21641345
Drug: SLV320 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV320 3.75 mg
Trial: 21641345
Drug: SLV320 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV320 7.5 mg
Trial: 19919976
Drug: SLV320 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV320 15 mg
Trial: 10930154
Drug: Antenatal monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal monotherapy predominantly with zidovudine (ZDV)
Trial: 26663387
Drug: LCZ696 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (400 mg, n = 21)
Trial: 29304421
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (40IU)
Trial: 24882155
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (20IU)
Trial: 1951158
Drug: 1.1 g
RxNorm normalized name: Giazo 1.1 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 g carbohydrate/kg body mass (LC)
Trial: 1951158
Drug: 2.2 g
RxNorm normalized name: Vaporizer Safeguard 2.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.2 g carbohydrate/kg body mass (HC)
Trial: 29860341
Drug: Intensive l-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive l-asparaginase therapy in the intermediate risk group
Trial: 21718265
Drug: Twice-weekly resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly resistance training
Trial: 23308123
Drug: Twice-weekly balance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly balance and tone training
Trial: 15923407
Drug: Dual combinations
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combinations of HIV-1 reverse transcriptase inhibitors
Trial: 15923407
Drug: Triple combinations
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combinations of HIV-1 reverse transcriptase inhibitors
Trial: 15694110
Drug: Transdermal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal placebo
Trial: 6303264
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (0.3 to 4 mg/kg)
Trial: 31425585
Drug: CSSO during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSSO during creep-feeding (CF) at 80 g/d per steer
Trial: 31425585
Drug: CSSO during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSSO during preconditioning (PC) at 150 g/d per steer
Trial: 12560628
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with 0.125 percent bupivocaine and morphine after combined general‐epidural anesthesia
Trial: 8565975
Drug: Warm underwater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm underwater water-jet massage (3 times, 20 min each) during treatment week
Trial: 2168152
Drug: Drug-resistant mutant
RxNorm normalized name: Streptococcus mutans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-resistant mutant [SR2‐410(r)]
Trial: 2168152
Drug: Drug-dependent mutant
RxNorm normalized name: Streptococcus mutans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-dependent mutant [SR2‐410(d)]
Trial: 14616929
Drug: L‐NG methylarginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NG methylarginine hydrochloride (L‐NMMA:546C88) 6 mg/kg
Trial: 30041183
Drug: LPNYL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPNYL treatment (energy density of 45 J/cm2, pulse width of 35 ms, spot size of 4 mm, frequency of 1 Hz, 6 treatments with 1-week intervals)
Trial: 30041183
Drug: Oral itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral itraconazole (drug group)
Trial: 22420596
Drug: Allopurinol augmentation
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol augmentation
Trial: 18779477
Drug: Implanted eyes
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implanted eyes (both doses)
Trial: 11502317
Drug: Sulfadoxine/pyrimethamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine) plus placebo
Trial: 11502317
Drug: Amodiaquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (25 mg/kg) plus placebo
Trial: 8489974
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml plain bupivacaine 0.5% injected at a rate of 0.05 ml/sec
Trial: 27376184
Drug: Arthrocentesis plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthrocentesis plus corticosteroid (CS) injection
Trial: 20828359
Drug: 5 cm²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 cm² rivastigmine patch (4.5 mg/24 h)
Trial: 20828359
Drug: 15 cm²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 cm² rivastigmine patch (13.3 mg/24 h)
Trial: 17680819
Drug: Controlled-release metoprolol
RxNorm normalized name: metoprolol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release metoprolol
Trial: 10870801
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg aspirin (daily for 1 week)
Trial: 10870801
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aspirin (daily for 1 week)
Trial: 26962518
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Depo‐Medrol injection plus full time neutral wrist splint (Group B)
Trial: 20663187
Drug: Dextrose 150
RxNorm normalized name: caffeine/dextrose 150 mg-300 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 150 g (600 kcals)
Trial: 7944997
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg tid for 6 months)
Trial: 2905252
Drug: Roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate 150 mg at bedtime
Trial: 2908751
Drug: Roxatidine acetate
RxNorm normalized name: roxatidine acetate
DrugBank: Roxatidine acetate (DB08806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxatidine acetate 150 mg post cenam nocte
Trial: 31941792
Drug: Double-injection costoclavicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection costoclavicular block
Trial: 31941792
Drug: Single-injection costoclavicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection costoclavicular block
Trial: 23737646
Drug: Immunotherapy (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (not explicitly detailed in the abstract)
Trial: 22921287
Drug: Mirodenafil 100
RxNorm normalized name: Mirodenafil
DrugBank: Mirodenafil (DB11792)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirodenafil 100 mg
Trial: 19068007
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Behavioral Treatment (IT)
Trial: 16912128
Drug: sitagliptin 25
RxNorm normalized name: SITagliptin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 25 mg
Trial: 16912128
Drug: sitagliptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 200 mg
Trial: 12388137
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oxymetholone daily for 12 weeks
Trial: 21854580
Drug: Oral topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral topiramate (n = 36) as an add-on to cognitive behavioural therapy (CBT)
Trial: 21854580
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) only (controls: n = 3 × 36)
Trial: 19250078
Drug: Gold-tip ablation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold-tip ablation catheter (group G)
Trial: 17915468
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of halotherapy (HT) and endobronchial helium‐neon laser irradiation (ELI) with traditional drug therapy (DT) in moderate persistent asthma
Trial: 11677365
Drug: NG-mononmethyl-l-arginine (co-infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-mononmethyl-l-arginine (co-infused with Ang(1-7))
Trial: 3286722
Drug: Inhaled gallopamil
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled gallopamil 2 mg
Trial: 3169109
Drug: Inhaled gallopamil
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled gallopamil 10 mg
Trial: 3286722
Drug: Inhaled gallopamil
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled gallopamil 20 mg
Trial: 3286722
Drug: Inhaled gallopamil
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled gallopamil 10 mg (exercise challenge)
Trial: 30202872
Drug: Standard MDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard MDA (annual praziquantel plus 6 monthly single-dose albendazole)
Trial: 29043996
Drug: rhBNP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBNP and dopamine combination treatment
Trial: 15948997
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg BIW
Trial: 23011358
Drug: Etanercept 10
RxNorm normalized name: Etanercept 10 mg powder for solution for injection vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 10 mg BIW
Trial: 19133409
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs supplementation (2.4 g/day for 24 weeks)
Trial: 12057618
Drug: HBsAg/AS04 hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg/AS04 hepatitis B vaccine (administered on a 0 and 6 months schedule)
Trial: 12057618
Drug: Licensed hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed hepatitis B vaccine (Engerix-B, administered on a 0, 1 and 6 months schedule)
Trial: 9839765
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of donepezil HCl (5 mg) and digoxin (0.25 mg)
Trial: 2547709
Drug: Caffeine (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3.3 mg/kg in grapefruit juice)
Trial: 899844
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) treatment at doses of 200, 400, or 600 mg per day
Trial: 27825272
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg twice daily for five days
Trial: 2904116
Drug: Propoxyphene (Darvon),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propoxyphene (Darvon), 100 mg q.i.d.
Trial: 2904116
Drug: Acetaminophen (Tylenol)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d.
Trial: 22777333
Drug: sequential IRIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential IRIS + bevacizumab
Trial: 20471302
Drug: Dynamic Contour
RxNorm normalized name: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic Contour Tonometry (DCT) with daily disposable hydrogel contact lens in situ
Trial: 20471302
Drug: Dynamic Contour
RxNorm normalized name: mometasone
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic Contour Tonometry (DCT) without daily disposable hydrogel contact lens
Trial: 17185423
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (2.2 g DHA and 1.1 g EPA/day)
Trial: 15218329
Drug: Intravenous L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-carnitine (20 mg/kg dry body weight three times weekly after haemodialysis) for 16 weeks
Trial: 28281731
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors
Trial: 9269694
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg daily
Trial: 3132028
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg alprenolol twice daily
Trial: 18458040
Drug: One course
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One course of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Trial: 16921009
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management intervention (monthly telephone contact and information/referral services)
Trial: 8421165
Drug: Monovalent B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent B (Mono B) followed by bivalent CR influenza A (Bi A) vaccine
Trial: 12968395
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (44 micrograms/ml of depigmented, polymerized allergen extract)
Trial: 12968395
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (no specific immunotherapy)
Trial: 6083597
Drug: 3-hydroxy-3-methylglutaric acid
RxNorm normalized name: 3-hydroxy-4-methoxybenzenesulfonic acid
DrugBank: Meglutol (DB04377)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-hydroxy-3-methylglutaric acid (HMGA) 1 g three times a day orally for 4 weeks
Trial: 30880072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3)
Trial: 30880072
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpelisib and olaparib
Trial: 22555869
Drug: i.v. pethidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pethidine plus EMLA cream (group A)
Trial: 22555869
Drug: i.v. pethidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. pethidine plus placebo hydrating cream (group B)
Trial: 18035190
Drug: GLY+RSG (glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLY+RSG (glyburide 10 or 20 mg plus rosiglitazone 8 mg)
Trial: 10655977
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg CuSO4
Trial: 10699742
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg Cu glycine chelate (CuG)
Trial: 10699742
Drug: Copper supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper supplementation (7 mg/d)
Trial: 9095564
Drug: Two 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 10 mg controlled-release oxycodone tablets
Trial: 3101709
Drug: Interferon-gamma (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma (50 micrograms, reduced to 20 or 10 micrograms in case of side effects), administered 3 to 7 times per week by subcutaneous route for 2 to 6 weeks.
Trial: 16202499
Drug: Clearfil SE
RxNorm normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clearfil SE Bond (SE) with gentle air-blowing (g)
Trial: 16202499
Drug: G-Bond (GB)
RxNorm normalized name: GB-13
DrugBank: GB-13 (DB18387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bond (GB) with strong air-blowing (s)
Trial: 10709161
Drug: Rizatriptan 10
RxNorm normalized name: rizatriptan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan 10 mg (6 days single-dose and 2 days multiple-dose 10 mg q 4 hours for three doses, total daily dose of 30 mg on Days 7 and 8)
Trial: 17073859
Drug: Single 30-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the tibial nerve (TN group, n=32)
Trial: 17073859
Drug: Two separate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two separate 15-ml injections targeting both tibial and common peroneal nerves (TN + CPN group, n=32)
Trial: 17073859
Drug: Single 30-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group, n=32)
Trial: 17073859
Drug: Single 30-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 30-ml injection of ropivacaine 7.5 mg/ml targeting the common peroneal nerve (CPN group)
Trial: 15204149
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg per day of cyclosporine A (CsA) for 4 weeks
Trial: 24515510
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU of daily oral vitamin D3
Trial: 24515510
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU of daily oral vitamin D3
Trial: 12883103
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behavioral therapy
Trial: 20870000
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy
Trial: 3081918
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg b.d.)
Trial: 1810260
Drug: Ranitidine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine and Theophylline (500 mg b.d.)
Trial: 1810260
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Theophylline (500 mg b.d.)
Trial: 6194037
Drug: 20% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Intralipid by intestinal infusion for 2 hours while 10% Intralipid was infused intravenously during the second hour
Trial: 15118280
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet agent or anticoagulant
Trial: 9382660
Drug: EDTU care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTU care (inhaled adrenergic agonists and steroids for up to 9 hours)
Trial: 8104738
Drug: Nonselective beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective beta-blocker propranolol
Trial: 8104738
Drug: Beta 1-selective
RxNorm normalized name: interleukin-1, beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 1-selective blocker metoprolol
Trial: 18326960
Drug: Irbesartan (ARB)
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan (ARB) monotherapy at maximal dose
Trial: 17132971
Drug: Memantine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10 mg b.i.d.; n=203)
Trial: 10699097
Drug: Early low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early low-dose indomethacin therapy